Antibacterial Drugs Market Size, Trends and Insights By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA, Others), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global Antibacterial Drugs Market is expected to record a CAGR of 5.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 51.55 billion. By 2032, the valuation is anticipated to reach USD 67.9 billion.
Antibacterial drugs can be derived from microorganisms like bacteria or molds, or they can be synthesized from scratch. These medications are designed to either eliminate bacteria or impede their growth. They play a pivotal role in modern healthcare, primarily in the treatment and prevention of infectious diseases, including urinary tract infections caused by bacteria like E. coli, S. aureus, and Streptococcus pyogenes.
In addition to urinary tract infections, antibacterial drugs are instrumental in combating contagious respiratory infections such as influenza (commonly known as the flu) and the common cold. These drugs function by either eradicating the microbes responsible for the infections or inhibiting their proliferation. The significance of antibacterial drugs extends to the treatment of various bacterial infections caused by pathogens like Escherichia coli and Klebsiella pneumonia, among others.
Furthermore, the rising incidence of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, human immunodeficiency virus infection (HIV/AIDS), and more underscores the crucial role these drugs play in safeguarding public health and driving market growth.
Antibacterial Drugs Market – Significant Growth Factors
The escalating challenge posed by bacterial infections and the rising need for innovative medications to combat bacterial diseases is driving the demand for next-generation antibiotics.
Moreover, the growing prevalence of antimicrobial resistance, primarily stemming from the excessive use of antibacterial treatments, is expected to prompt a shift in prescription practices towards advanced therapies for the management of infectious diseases.
According to data from the Centers for Disease Control and Prevention (CDC), Antimicrobial Resistance (AMR) affects over 2.9 million individuals annually in the United States alone. This substantial burden underscores the pressing demand for antibiotics, driven by a notable increase in the incidence of infectious diseases.
Diarrhea is a prominent cause of child mortality worldwide, as highlighted by the World Health Organization (WHO), necessitating antibiotic interventions to prevent severe illness. The prevalence of various infectious diseases, including pneumonia, lower respiratory infections, and Hospital-Acquired Infections (HAIs), is contributing significantly to the growth of the market.
Furthermore, the growing disease burden is prompting both governmental and non-governmental organizations to invest in research and development (R&D) endeavours aimed at creating novel drugs.
For instance, government agencies like BARDA have partnered with multiple companies to support the development of new therapies for infectious diseases. This collaborative effort is a response to the increasing awareness of antibiotic-resistant infections, prompting pharmaceutical and biopharmaceutical firms to prioritize the creation of combination therapies.
These therapies are designed to yield synergistic and additive effects, offering enhanced efficacy in treating infections. As an example, in March 2022, Venatorx Pharmaceuticals achieved positive clinical phase III results for its combination antibiotic therapy, cefepime-taniborbactam, designed for the treatment of complicated urinary tract infections in adults.
Furthermore, pharmaceutical companies are dedicating more resources to the development of innovative therapies for infectious diseases. According to the Pew Charitable Trust, as of December 2020, nearly 45 promising antibiotic molecules were under investigation for managing severe bacterial infections, reflecting the industry’s commitment to addressing this critical healthcare challenge.
Antibacterial Drugs Market – Mergers and Acquisitions
- Pfizer’s Acquisition of AstraZeneca’s Antibiotics Business (2016): Pfizer, a leading pharmaceutical company, acquired AstraZeneca’s antibiotics portfolio, strengthening its position in the antibiotics market. This strategic move allowed Pfizer to expand its antibiotic offerings and enhance its infectious disease portfolio.
- Melinta Therapeutics’ Acquisition of Cempra (2017): Melinta Therapeutics, a company specializing in antibiotics, acquired Cempra, a clinical-stage pharmaceutical company. This acquisition bolstered Melinta’s antibiotic pipeline and expanded its capabilities in developing antibiotics for bacterial infections.
- Merck’s Acquisition of Cubist Pharmaceuticals (2015): Merck, a global pharmaceutical company, acquired Cubist Pharmaceuticals, known for its expertise in antibiotics. This acquisition aimed to diversify Merck’s product portfolio and strengthen its presence in the antibiotics market.
- Teva Pharmaceutical’s Acquisition of Allergan’s Generic Business (2016): Teva Pharmaceutical Industries acquired Allergan’s generic drug business, which included a range of antibiotic products. This acquisition allowed Teva to expand its generic antibiotic offerings and global market presence.
- Summit Therapeutics’ Acquisition of Discuva (2018): Summit Therapeutics, a biotechnology company, acquired Discuva, a developer of novel antibiotics. This acquisition enriched Summit’s antibiotic research and development capabilities, particularly in addressing antibiotic-resistant bacteria.
- Nabriva Therapeutics’ Acquisition of Zavante Therapeutics (2018): Nabriva Therapeutics acquired Zavante Therapeutics, a company focused on developing antibiotics for challenging infections. This strategic move bolstered Nabriva’s antibiotics portfolio and research pipeline.
- Merck’s Acquisition of Peloton Therapeutics (2019): Merck acquired Peloton Therapeutics, which had antibiotic development programs in its pipeline. This acquisition aligned with Merck’s commitment to addressing unmet medical needs, including antibiotic-resistant infections.
- Sumitomo Dainippon Pharma’s Acquisition of Roivant Sciences (2020): Sumitomo Dainippon Pharma acquired Roivant Sciences, which included Roivant’s subsidiary, Myovant Sciences, engaged in antibiotic research and development. This acquisition expanded Sumitomo Dainippon Pharma’s presence in the infectious diseases and antibiotics space.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Antibacterial Drugs Market | Generic Drug Market | Antimalarial Drugs Market |
| CAGR 5.6% (Approx) | CAGR 6.2% (Approx) | CAGR 4.6% (Approx) |
| USD 67.9 Billion by 2032 | USD 675.18 Billion by 2030 | USD 1202.21 Million by 2030 |
Antibacterial Drugs Market – Significant Threats
- Antimicrobial Resistance (AMR): The development of antimicrobial resistance by bacteria poses a significant threat. Overuse and misuse of antibiotics contribute to the emergence of drug-resistant strains, making it challenging to treat infections effectively.
- Limited Pipeline: The antibiotic development pipeline is relatively limited compared to other therapeutic areas. The high costs and challenges associated with antibiotic research and development have led many pharmaceutical companies to deprioritize this area, potentially resulting in a scarcity of new antibiotics.
- Economic Viability: Antibiotic development faces economic challenges. Short treatment durations and the need for responsible antibiotic stewardship programs can limit the financial returns for pharmaceutical companies, discouraging investment in new antibiotic research.
- Regulatory Hurdles: Regulatory approval processes for antibiotics can be stringent, requiring extensive clinical trials and evidence of safety and efficacy. Meeting these regulatory requirements adds to the cost and time involved in bringing new antibiotics to market.
- Low Pricing: Competitive pricing pressures and the need for affordable antibiotics can lead to lower profit margins for manufacturers, affecting the economic viability of antibiotic production.
- Complexity of Antibiotic Resistance: Bacterial resistance mechanisms are complex and continually evolving. Developing antibiotics that can effectively combat resistant strains is a significant challenge.
- Biosecurity Concerns: The potential misuse or biosecurity threats associated with the development and distribution of antibiotics pose security concerns at a global level.
- Lack of Novel Mechanisms: There is a need for antibiotics with novel mechanisms of action to combat resistant bacteria effectively. The absence of such innovations limits the arsenal of available treatments.
- Global Health Security: Infectious diseases, including those caused by drug-resistant bacteria, can have global health security implications. Outbreaks and pandemics can strain healthcare systems and disrupt economies.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 53.18 Billion |
| Projected Market Size in 2032 | USD 67.9 Billion |
| Market Size in 2022 | USD 51.55 Billion |
| CAGR Growth Rate | 5.6% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Drug Class, Type, Action Mechanism and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Category-Wise Insights
Based on the Action Mechanism:
In 2022, the cell wall synthesis inhibitor segment dominated the market, commanding a significant share of 53.5%. This substantial market share can be attributed to several factors, including the broad-spectrum action mechanisms exhibited by these antibiotics and their frequent prescription for the treatment of both gram-negative and gram-positive bacterial infections.
Notably, antibiotics like carbapenems, penicillin, and cephalosporins, which fall under the category of cell wall synthesis inhibitors, are among the most commonly used drugs for managing bacterial infections.
Furthermore, the cell wall synthesis inhibitor segment is experiencing growth due to increased research activities and a rising number of regulatory approvals for these antibiotics. These factors collectively contribute to the segment’s dominance in the market.
Based on Type:
In 2022, the generic antibiotics segment emerged as the clear leader in the overall market, commanding a substantial revenue share of 81.7%. Furthermore, it is projected to exhibit the most rapid growth rate over the forecast period. Several factors contribute to the dominance of this segment.
Firstly, the widespread adoption of generic antibiotic formulations can be attributed to their affordability. These cost-effective alternatives make antibiotics more accessible to a broader population, thereby increasing their demand and market share. Secondly, the presence of numerous manufacturers in the generic antibiotics segment leads to heightened competition and subsequently empowers buyers with greater bargaining power.
This competitive landscape further enhances the segment’s prominence within the market. Moreover, a supportive regulatory framework plays a pivotal role in driving the growth of generic antibiotics. Regulatory agencies facilitate the approval and distribution of generic preparations, encouraging their utilization within the healthcare sector.
Lastly, government initiatives favoring the promotion of generic antibiotic formulations, along with initiatives aimed at enhancing access to generic drugs, are acting as catalysts for the segment’s expansion. These combined factors position generic antibiotics as the dominant force within the market.
Antibacterial Drugs Market – Regional Analysis
North America:
- North America, led by the United States and Canada, is a prominent player in the Antibacterial Drugs market. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, and significant investments in research and development.
- Rising concerns about antimicrobial resistance and the need for novel antibiotics drive the demand for antibacterial drugs in North America.
Europe:
- Europe, including countries like the United Kingdom, Germany, and France, is a well-established market for antibacterial drugs. The region’s healthcare systems focus on infection control and antibiotic stewardship programs.
- Regulatory agencies, such as the European Medicines Agency (EMA), play a crucial role in approving and monitoring antibacterial drugs.
Asia-Pacific:
- The Asia-Pacific region, particularly countries like China, India, and Japan, presents substantial growth opportunities in the Antibacterial Drugs market. The region’s population density and diverse healthcare landscapes contribute to the demand for antibiotics.
- Growing awareness of infectious diseases, improving healthcare infrastructure, and the presence of a vast pharmaceutical manufacturing base are key factors in the market’s expansion.
Latin America:
- Latin America is witnessing increased demand for antibacterial drugs, primarily due to a rising burden of infectious diseases. Countries like Brazil and Mexico are significant contributors to market growth.
- Economic disparities and variations in healthcare access across the region influence market dynamics.
Middle East and Africa:
- The Middle East and Africa region exhibit variations in the prevalence of infectious diseases. Some countries face a high burden of bacterial infections, while others have lower rates.
- Efforts to improve healthcare access, combat infectious diseases, and enhance antibiotic availability contribute to market growth.
List of the prominent players in the Antibacterial Drugs Market:
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals Inc.
- Viatris Inc.
- Melinta Therapeutics LLC
- Cipla Inc.
- Shionogi & Co. Ltd.
- KYORIN Pharmaceutical Co. Ltd.
- GSK plc
- Nabriva Therapeutics PLC
- Others
The Antibacterial Drugs Market is segmented as follows:
By Drug Class
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolides
- Carbapenems
- Aminoglycosides
- Sulfonamides
- 7-ACA
- Others
By Type
- Branded Antibiotics
- Generic Antibiotics
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors
- Mycolic Acid Inhibitors
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Antibacterial Drugs Market, (2024 – 2033) (USD Billion)
- 2.2 Global Antibacterial Drugs Market : snapshot
- Chapter 3. Global Antibacterial Drugs Market – Industry Analysis
- 3.1 Antibacterial Drugs Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Antimicrobial Resistance (AMR)
- 3.2.2 Infectious Disease Burden
- 3.2.3 Research and Development
- 3.2.4 Regulatory Initiatives
- 3.2.5 Patient Demographics
- 3.2.6 Public Health Initiatives
- 3.2.7 Global Health Security
- 3.2.8 Economic Factors
- 3.2.9 Combination Therapies
- 3.2.10 Patient Care Settings
- 3.2.11 Healthcare Infrastructure
- 3.2.12 Environmental Concerns.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Drug Class
- 3.7.2 Market attractiveness analysis By Type
- 3.7.3 Market attractiveness analysis By Action Mechanism
- Chapter 4. Global Antibacterial Drugs Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Antibacterial Drugs Market: company market share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Antibacterial Drugs Market – Drug Class Analysis
- 5.1 Global Antibacterial Drugs Market overview: By Drug Class
- 5.1.1 Global Antibacterial Drugs Market share, By Drug Class, 2022 and – 2033
- 5.2 Cephalosporin
- 5.2.1 Global Antibacterial Drugs Market by Cephalosporin, 2024 – 2033 (USD Billion)
- 5.3 Penicillin
- 5.3.1 Global Antibacterial Drugs Market by Penicillin, 2024 – 2033 (USD Billion)
- 5.4 Fluoroquinolone
- 5.4.1 Global Antibacterial Drugs Market by Fluoroquinolone, 2024 – 2033 (USD Billion)
- 5.5 Macrolides
- 5.5.1 Global Antibacterial Drugs Market by Macrolides, 2024 – 2033 (USD Billion)
- 5.6 Carbapenems
- 5.6.1 Global Antibacterial Drugs Market by Carbapenems, 2024 – 2033 (USD Billion)
- 5.7 Aminoglycosides
- 5.7.1 Global Antibacterial Drugs Market by Aminoglycosides, 2024 – 2033 (USD Billion)
- 5.8 Sulfonamides
- 5.8.1 Global Antibacterial Drugs Market by Sulfonamides, 2024 – 2033 (USD Billion)
- 5.9 7-ACA
- 5.9.1 Global Antibacterial Drugs Market by 7-ACA, 2024 – 2033 (USD Billion)
- 5.10 Others
- 5.10.1 Global Antibacterial Drugs Market by Others, 2024 – 2033 (USD Billion)
- 5.1 Global Antibacterial Drugs Market overview: By Drug Class
- Chapter 6. Global Antibacterial Drugs Market – Type Analysis
- 6.1 Global Antibacterial Drugs Market overview: By Type
- 6.1.1 Global Antibacterial Drugs Market share, By Type , 2022 and – 2033
- 6.2 Branded Antibiotics
- 6.2.1 Global Antibacterial Drugs Market by Branded Antibiotics, 2024 – 2033 (USD Billion)
- 6.3 Generic Antibiotics
- 6.3.1 Global Antibacterial Drugs Market by Generic Antibiotics, 2024 – 2033 (USD Billion)
- 6.1 Global Antibacterial Drugs Market overview: By Type
- Chapter 7. Global Antibacterial Drugs Market – Action Mechanism Analysis
- 7.1 Global Antibacterial Drugs Market overview: By Action Mechanism
- 7.1.1 Global Antibacterial Drugs Market share, By Action Mechanism, 2022 and – 2033
- 7.2 Cell Wall Synthesis Inhibitors
- 7.2.1 Global Antibacterial Drugs Market by Cell Wall Synthesis Inhibitors, 2024 – 2033 (USD Billion)
- 7.3 Protein Synthesis Inhibitors
- 7.3.1 Global Antibacterial Drugs Market by Protein Synthesis Inhibitors, 2024 – 2033 (USD Billion)
- 7.4 DNA Synthesis Inhibitors
- 7.4.1 Global Antibacterial Drugs Market by DNA Synthesis Inhibitors, 2024 – 2033 (USD Billion)
- 7.5 RNA Synthesis Inhibitors
- 7.5.1 Global Antibacterial Drugs Market by RNA Synthesis Inhibitors, 2024 – 2033 (USD Billion)
- 7.6 Mycolic Acid Inhibitors
- 7.6.1 Global Antibacterial Drugs Market by Mycolic Acid Inhibitors, 2024 – 2033 (USD Billion)
- 7.7 Others
- 7.7.1 Global Antibacterial Drugs Market by Others, 2024 – 2033 (USD Billion)
- 7.1 Global Antibacterial Drugs Market overview: By Action Mechanism
- Chapter 8. Antibacterial Drugs Market – Regional Analysis
- 8.1 Global Antibacterial Drugs Market Regional Overview
- 8.2 Global Antibacterial Drugs Market Share, by Region, 2022 & – 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America Antibacterial Drugs Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.4 North America Antibacterial Drugs Market, by Drug Class, 2024 – 2033
- 8.4.1 North America Antibacterial Drugs Market, by Drug Class, 2024 – 2033 (USD Billion)
- 8.5 North America Antibacterial Drugs Market, by Type , 2024 – 2033
- 8.5.1 North America Antibacterial Drugs Market, by Type , 2024 – 2033 (USD Billion)
- 8.6 North America Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033
- 8.6.1 North America Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033 (USD Billion)
- 8.7. Europe
- 8.7.1 Europe Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.7.1.1 Europe Antibacterial Drugs Market, by Country, 2024 – 2033 (USD Billion)
- 8.7.1 Europe Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.8 Europe Antibacterial Drugs Market, by Drug Class, 2024 – 2033
- 8.8.1 Europe Antibacterial Drugs Market, by Drug Class, 2024 – 2033 (USD Billion)
- 8.9 Europe Antibacterial Drugs Market, by Type , 2024 – 2033
- 8.9.1 Europe Antibacterial Drugs Market, by Type , 2024 – 2033 (USD Billion)
- 8.10 Europe Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033
- 8.10.1 Europe Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033 (USD Billion)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.11.1.1 Asia Pacific Antibacterial Drugs Market, by Country, 2024 – 2033 (USD Billion)
- 8.11.1 Asia Pacific Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.12 Asia Pacific Antibacterial Drugs Market, by Drug Class, 2024 – 2033
- 8.12.1 Asia Pacific Antibacterial Drugs Market, by Drug Class, 2024 – 2033 (USD Billion)
- 8.13 Asia Pacific Antibacterial Drugs Market, by Type , 2024 – 2033
- 8.13.1 Asia Pacific Antibacterial Drugs Market, by Type , 2024 – 2033 (USD Billion)
- 8.14 Asia Pacific Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033
- 8.14.1 Asia Pacific Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033 (USD Billion)
- 8.15. Latin America
- 8.15.1 Latin America Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.15.1.1 Latin America Antibacterial Drugs Market, by Country, 2024 – 2033 (USD Billion)
- 8.15.1 Latin America Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.16 Latin America Antibacterial Drugs Market, by Drug Class, 2024 – 2033
- 8.16.1 Latin America Antibacterial Drugs Market, by Drug Class, 2024 – 2033 (USD Billion)
- 8.17 Latin America Antibacterial Drugs Market, by Type , 2024 – 2033
- 8.17.1 Latin America Antibacterial Drugs Market, by Type , 2024 – 2033 (USD Billion)
- 8.18 Latin America Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033
- 8.18.1 Latin America Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033 (USD Billion)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.19.1.1 The Middle-East and Africa Antibacterial Drugs Market, by Country, 2024 – 2033 (USD Billion)
- 8.19.1 The Middle-East and Africa Antibacterial Drugs Market, 2024 – 2033 (USD Billion)
- 8.20 The Middle-East and Africa Antibacterial Drugs Market, by Drug Class, 2024 – 2033
- 8.20.1 The Middle-East and Africa Antibacterial Drugs Market, by Drug Class, 2024 – 2033 (USD Billion)
- 8.21 The Middle-East and Africa Antibacterial Drugs Market, by Type , 2024 – 2033
- 8.21.1 The Middle-East and Africa Antibacterial Drugs Market, by Type , 2024 – 2033 (USD Billion)
- 8.22 The Middle-East and Africa Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033
- 8.22.1 The Middle-East and Africa Antibacterial Drugs Market, by Action Mechanism, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 AbbVie Inc.
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Pfizer Inc.
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Novartis AG
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Merck & Co. Inc.
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Teva Pharmaceutical Industries Ltd.
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Lupin Pharmaceuticals Inc.
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Viatris Inc.
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Melinta Therapeutics LLC
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Cipla Inc.
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Shionogi & Co. Ltd.
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 KYORIN Pharmaceutical Co. Ltd.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 GSK plc
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Nabriva Therapeutics PLC
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Others.
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.1 AbbVie Inc.
List Of Figures
Figures No 1 to 33
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals Inc.
- Viatris Inc.
- Melinta Therapeutics LLC
- Cipla Inc.
- Shionogi & Co. Ltd.
- KYORIN Pharmaceutical Co. Ltd.
- GSK plc
- Nabriva Therapeutics PLC
- Others
FAQs
The key factors driving the Market are Antimicrobial Resistance (AMR), Infectious Disease Burden, Research and Development, Regulatory Initiatives, Patient Demographics, Public Health Initiatives, Global Health Security, Economic Factors, Combination Therapies, Patient Care Settings, Healthcare Infrastructure And Environmental Concerns.
The “Drug Class” category dominated the market in 2022.
The key players in the market are AbbVie Inc., Pfizer Inc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Lupin Pharmaceuticals Inc., Viatris Inc., Melinta Therapeutics LLC, Cipla Inc., Shionogi & Co. Ltd., KYORIN Pharmaceutical Co. Ltd., GSK plc, Nabriva Therapeutics PLC, Others.
“North America” had the largest share in the Antibacterial Drugs Market.
The global market is projected to grow at a CAGR of 5.6% during the forecast period, 2023-2032.
The Antibacterial Drugs Market size was valued at USD 51.55 Billion in 2022.
PURCHASE OPTIONS
What You Get :
- PDF Report Format.
- Can be accessible by 1 single user.
- Free 25% or 40 hours of customisation.
- Free post-sale service assistance.
- 15% discount on your next purchase.
- Dedicated account Associate .
- Permission to print the report.
- Service guarantee available.
- PDF and Excel Datasheet Formats.
- Can be accessible upto 2 to 5 users.
- Free 35% or 60 hours of customisation.
- Free post-sale service assistance.
- 25% discount on your next purchase.
- Service guarantee available.
- Personalised market brief by author.
- Permission to print the report.
- Report in your Language.
- PDF, Excel and Power Point.
- Can be accessible by unlimited users.
- Free 40% or 80 hours of customisation.
- Free post-sale service assistance.
- 30% discount on your next purchase.
- Permission to print the report.
- Dedicated account manager.
- Service guarantee available.
- Report in your Language.
- Excel Datasheet Format.
- Customized access as per user request.
- Upgradable to other licenses.
- 15% discount on your next purchase.
- Free 20% or 10 hours of customisation.
- PDF, Excel, Power Point and Power BI.
- Every Year Free Update ( Apr – Apr)
- Personalized market brief by author
- Can be accessible by unlimited users.
- Free 50% or 90 hours of customization.
- Up to 50 Company Profiles
- Free post-sale service assistance with guarantee
- 40% discount on your next purchase.
- Permission to print the report.
- Dedicated account team.
- Service guarantee available.
- Report in your Language.